Loading...
SDZ logo

Sandoz Group AGSWX:SDZ Stok Raporu

Piyasa Değeri CHF 28.4b
Hisse Fiyatı
CHF 65.60
CHF 81.99
20.0% değerinin altında içsel indirim
1Y57.0%
7D1.8%
1D
Portföy Değeri
​
Görünüm

Sandoz Group AG

SWX:SDZ Stok Raporu

Piyasa değeri: CHF 28.4b

Sandoz Group (SDZ) Hisse Özeti

Sandoz Group AG, dünya çapında jenerik farmasötikler ve biyobenzerler geliştirmekte, üretmekte ve pazarlamaktadır. Daha fazla detay

Ödüller

Adil değer tahminimizden 38.4% daha düşük bir oranda işlem görüyor

Kazançların yılda 17.04% oranında artması öngörülüyor

Risk Analizi

Risk kontrollerimizden SDZ için herhangi bir risk tespit edilmedi.

SDZ Community Fair Values

Create Narrative

See what 54 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives

Sandoz Group AG Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Sandoz Group
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıCHF 65.60
52 Haftanın En Yüksek SeviyesiCHF 72.70
52 Haftanın En Düşük SeviyesiCHF 41.43
Beta0.53
1 Aylık Değişim4.89%
3 Aylık Değişim0.24%
1 Yıllık Değişim57.01%
3 Yıllık Değişimn/a
5 Yıllık Değişimn/a
Halka arzdan bu yana değişim169.40%

Son Haberler & Güncellemeler

Anlatı Güncellemesi • May 28

SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E

Analysts have adjusted the Sandoz Group price target slightly higher, with the updated fair value estimate moving from about CHF 66.01 to CHF 66.36 as they factor in modestly different assumptions for growth, margins and future P/E, following a mix of recent upgrades, initiations and target changes across the Street. Analyst Commentary Recent research on Sandoz Group reflects a mix of optimism and caution, with several firms adjusting ratings and price targets in different directions.
Anlatı Güncellemesi • May 01

SDZ: Mixed Rating Shifts And Biosimilar Deals Will Shape Future P/E

The updated analyst price target for Sandoz Group has been revised by approximately CHF 1 higher, reflecting modestly adjusted assumptions around fair value, revenue growth, profit margins and future P/E as analysts balance recent target changes and rating shifts across major banks. Analyst Commentary Recent Street research around Sandoz Group shows a mix of optimism on the company’s long term potential and caution on how current pricing and expectations line up with execution risks.
Anlatı Güncellemesi • Apr 16

SDZ: Elevated Expectations Will Test Execution On Biosimilar Expansion Plans

Analysts have raised the Sandoz Group price target by roughly CHF 2 per share, reflecting a higher assumed fair value. This is supported by a series of recent CHF 3 to CHF 9 target increases from major banks and generally constructive views, despite some rating downgrades.
Anlatı Güncellemesi • Apr 01

SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating

Analysts have lifted the price target for Sandoz Group from CHF 60.37 to CHF 81.99, citing recent initiations, upgrades and target increases that highlight a higher assumed future P/E multiple and slightly improved profit margin expectations, despite more measured revenue growth assumptions. Analyst Commentary Recent Street research on Sandoz Group presents a mixed picture, but there is a clear strand of optimism around execution, earnings quality and the scope for the shares to support higher valuation multiples.

Recent updates

Anlatı Güncellemesi • May 28

SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E

Analysts have adjusted the Sandoz Group price target slightly higher, with the updated fair value estimate moving from about CHF 66.01 to CHF 66.36 as they factor in modestly different assumptions for growth, margins and future P/E, following a mix of recent upgrades, initiations and target changes across the Street. Analyst Commentary Recent research on Sandoz Group reflects a mix of optimism and caution, with several firms adjusting ratings and price targets in different directions.
Anlatı Güncellemesi • May 01

SDZ: Mixed Rating Shifts And Biosimilar Deals Will Shape Future P/E

The updated analyst price target for Sandoz Group has been revised by approximately CHF 1 higher, reflecting modestly adjusted assumptions around fair value, revenue growth, profit margins and future P/E as analysts balance recent target changes and rating shifts across major banks. Analyst Commentary Recent Street research around Sandoz Group shows a mix of optimism on the company’s long term potential and caution on how current pricing and expectations line up with execution risks.
Anlatı Güncellemesi • Apr 16

SDZ: Elevated Expectations Will Test Execution On Biosimilar Expansion Plans

Analysts have raised the Sandoz Group price target by roughly CHF 2 per share, reflecting a higher assumed fair value. This is supported by a series of recent CHF 3 to CHF 9 target increases from major banks and generally constructive views, despite some rating downgrades.
Anlatı Güncellemesi • Apr 01

SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating

Analysts have lifted the price target for Sandoz Group from CHF 60.37 to CHF 81.99, citing recent initiations, upgrades and target increases that highlight a higher assumed future P/E multiple and slightly improved profit margin expectations, despite more measured revenue growth assumptions. Analyst Commentary Recent Street research on Sandoz Group presents a mixed picture, but there is a clear strand of optimism around execution, earnings quality and the scope for the shares to support higher valuation multiples.
Anlatı Güncellemesi • Mar 18

SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E

Analysts have lifted the Fair Value estimate for Sandoz Group from CHF 62.57 to CHF 65.45. This reflects a series of higher Street price targets around CHF 62 to CHF 75 and updated assumptions for modestly higher revenue growth, a slightly lower profit margin profile, and a higher future P/E multiple.
Anlatı Güncellemesi • Mar 04

SDZ: Mixed Rating Shifts And Biosimilar Pipeline Progress Will Shape Future P/E

Analysts have lifted their fair value estimate for Sandoz to about CHF 63, reflecting updated assumptions for slightly lower revenue growth, a higher profit margin and a modestly lower future P/E, along with recent mixed rating changes and higher price targets in the CHF 70 to CHF 75 range. Analyst Commentary Recent Street research on Sandoz shows a mix of optimism and caution, with price targets now clustering in the CHF 70 to CHF 75 range and ratings shifting closer to neutral.
Anlatı Güncellemesi • Feb 18

SDZ: Richer Future P/E Assumptions Will Test Biosimilar Execution Confidence

Our latest narrative update on Sandoz Group reflects a higher implied fair value of CHF 58.42, up from CHF 52.75, supported by recent analyst price target increases and a willingness to assign a richer future P/E multiple. Analyst Commentary Recent Street research around Sandoz Group has centered on a series of price target revisions and at least one rating upgrade, which together frame how the analyst community is thinking about valuation, execution risk, and growth potential.
Anlatı Güncellemesi • Feb 03

SDZ: Elevated Expectations Will Confront Ongoing Execution And Manufacturing Setbacks

Analysts have raised their average price target on Sandoz Group by CHF 3 to CHF 60, citing updated assumptions for revenue growth, profit margins and future P/E, in line with recent target increases from several major banks. Analyst Commentary Recent Street research on Sandoz Group has largely focused on recalibrating price targets to reflect updated views on revenue growth, profitability and valuation multiples.
Anlatı Güncellemesi • Jan 20

SDZ: Rising Biosimilar Pipeline Will Face Ongoing Execution And Manufacturing Risks

Narrative Update The updated analyst price target for Sandoz Group reflects a modestly lower fair value estimate alongside slightly higher revenue growth and profit margin assumptions. Recent Street research citing price target moves to CHF 60 and CHF 70 indicates that analysts see room for the shares to better reflect these revised expectations.
Anlatı Güncellemesi • Jan 06

SDZ: Elevated Biosimilar Ambitions Will Face Ongoing Execution And Manufacturing Risks

Analysts have lifted their average price targets on Sandoz Group into a CHF 49 to CHF 70 range, and our updated fair value of CHF 44.42 nudges slightly lower as higher assumed profit margins and revenue growth are offset by a reduced future P/E multiple. Analyst Commentary Recent Street research on Sandoz Group shows a cluster of higher price targets, with targets in the CHF 49 to CHF 70 range.
Anlatı Güncellemesi • Dec 21

SDZ: Elevated Expectations Will Face Execution Risks In Biosimilars Expansion

Sandoz Group's analyst price target has been lifted by roughly CHF 6.50 to around CHF 60, as analysts now factor in stronger revenue growth, modestly higher profit margins, and a richer forward valuation multiple. Analyst Commentary Recent Street research has been broadly constructive on Sandoz Group, with several major firms lifting their price targets into the CHF 49 to CHF 60 range and maintaining positive ratings.
Anlatı Güncellemesi • Dec 07

SDZ: Biosimilar Launch Execution Will Shape Future Multiple And Risk Balance

Sandoz Group’s analyst price target has been nudged higher, with fair value estimates rising by about CHF 1.10 to CHF 52.75 as analysts point to sustained revenue growth expectations and a modestly higher future P E multiple, despite slightly lower margin forecasts. Analyst Commentary Bullish analysts have recently raised their price targets into the CHF 55 to CHF 60 range, signaling growing confidence that Sandoz can sustain above market growth and support a higher valuation multiple.
Anlatı Güncellemesi • Nov 23

SDZ: Sustained Revenue Momentum And Margin Focus Will Shape Fair Value Ahead

The analyst consensus price target for Sandoz Group has increased to CHF 60 from CHF 55. Analysts cite improved margin outlook and sustained revenue growth as key factors supporting the upward revision.
Anlatı Güncellemesi • Nov 09

SDZ: Recent US Launch and European Expansion Will Influence Near-Term Performance

The average analyst price target for Sandoz Group has increased from CHF 50.33 to CHF 52.05, reflecting improved revenue growth forecasts and recent supportive analyst research updates. Analyst Commentary Recent analyst updates reflect a mix of optimism and caution regarding Sandoz Group's valuation, growth prospects, and execution.
Anlatı Güncellemesi • Oct 26

Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach

The analyst consensus price target for Sandoz Group rose modestly, increasing from CHF 50.20 to CHF 50.33. Analysts cited stronger revenue growth and improving profit margins in their updated outlooks.
Anlatı Güncellemesi • Oct 12

Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities

The analyst price target for Sandoz Group has increased by CHF 0.81. This reflects positive sentiment from analysts who cite strong revenue growth and continued profitability improvements as supporting factors.
Yeni Anlatı • Aug 17

Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities

Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.
Analiz Makalesi • Jun 25

Sentiment Still Eluding Sandoz Group AG (VTX:SDZ)

You may think that with a price-to-sales (or "P/S") ratio of 2.2x Sandoz Group AG ( VTX:SDZ ) is definitely a stock...

Hissedar Getirileri

SDZCH PharmaceuticalsCH Pazar
7D1.8%-1.0%0.6%
1Y57.0%27.1%9.2%

Getiri vs. Endüstri: SDZ geçen yıl % 27.1 oranında getiri sağlayan Swiss Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: SDZ geçen yıl % 9.2 oranında getiri sağlayan Swiss Piyasasını aştı.

Fiyat Oynaklığı

Is SDZ's price volatile compared to industry and market?
SDZ volatility
SDZ Average Weekly Movement4.2%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement4.5%
10% most volatile stocks in CH Market8.2%
10% least volatile stocks in CH Market2.4%

İstikrarlı Hisse Senedi Fiyatı: SDZ son 3 ayda Swiss piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: SDZ 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
188622,356Richard Saynorwww.sandoz.com

Sandoz Group AG, dünya çapında jenerik farmasötikler ve biyobenzerler geliştirmekte, üretmekte ve pazarlamaktadır. Şirket, kardiyovasküler, merkezi sinir sistemi, onkoloji, bulaşıcı hastalıklar, ağrı ve solunum, diyabet, immünoloji, endokrinoloji, hematoloji ve oftalmoloji dahil olmak üzere terapötik alanları kapsamaktadır. Ayrıca aktif farmasötik bileşenler ve bitmiş dozaj formlarından oluşan bir portföy sunmaktadır.

Sandoz Group AG Temel Bilgiler Özeti

Sandoz Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
SDZ temel i̇stati̇sti̇kler
Piyasa değeriCHF 28.38b
Kazançlar(TTM)CHF 713.32m
Gelir(TTM)CHF 8.71b
39.8x
F/K Oranı
3.3x
P/S Oranı

SDZ aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
SDZ gelir tablosu (TTM)
GelirUS$11.16b
Gelir MaliyetiUS$5.86b
Brüt KârUS$5.30b
Diğer GiderlerUS$4.39b
KazançlarUS$914.00m

Son Raporlanan Kazançlar

Dec 31, 2025

Sonraki Kazanç Tarihi

Aug 05, 2026

Hisse başına kazanç (EPS)2.11
Brüt Marj47.50%
Net Kâr Marjı8.19%
Borç/Özkaynak Oranı56.6%

SDZ uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

1.2%
Mevcut Temettü Verimi
48%
Ödeme Oranı

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/06/01 08:08
Gün Sonu Hisse Fiyatı2026/05/29 00:00
Kazançlar2025/12/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Sandoz Group AG 38 Bu analistlerden 15, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Emily FieldBarclays
James GordonBarclays
Sidhartha ModiBarclays